Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have earned an average rating of "Buy" from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $43.00.

BCAX has been the topic of a number of analyst reports. Stifel Nicolaus began coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating and a $47.00 price target on the stock. Cantor Fitzgerald began coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating on the stock. Rodman & Renshaw initiated coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating and a $48.00 price target for the company. Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price objective on the stock. Finally, HC Wainwright assumed coverage on shares of Bicara Therapeutics in a research report on Friday, December 6th. They issued a "buy" rating and a $42.00 target price for the company.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in Bicara Therapeutics in the 4th quarter valued at approximately $147,000. Cinctive Capital Management LP bought a new position in shares of Bicara Therapeutics in the 3rd quarter valued at $229,000. Barclays PLC acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at $255,000. Jane Street Group LLC acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at $309,000. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in Bicara Therapeutics during the 3rd quarter worth $358,000.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock traded up $0.23 during trading on Monday, reaching $12.11. The company's stock had a trading volume of 234,941 shares, compared to its average volume of 542,115. The firm's 50-day moving average price is $17.87. Bicara Therapeutics has a 52 week low of $11.56 and a 52 week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). Equities research analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.